<DOC>
	<DOCNO>NCT02586831</DOCNO>
	<brief_summary>To assess whether difference endogenous insulin secretion , measure stimulate C-peptide secretion ( area curve 4-hour mixed meal tolerance test ) , 1 year visit , study subject receive combinational therapy versus receive placebo . The study also examine effect propose treatment immunological outcome , specifically proportion regulatory T cell 1 year visit .</brief_summary>
	<brief_title>Diabetes Islet Preservation Immune Treatment</brief_title>
	<detailed_description>There critical need test therapy afford long-lasting immunomodulation combine use short course deplete agent , chronic use drug promote immunoregulation critically control rebound effector population , together intervention quell inflammation support beta cell function glucose metabolism . Such combined regimen would rely low dos many agent , increase safety tolerability . Here , propose combinatorial regimen base administration drug already FDA approve market , use clinical trial patient T1D , alone combination . This trial test regimen propose , first time combine agent , successful preserve insulin secretion recent onset type 1 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients must meet follow criterion eligible participate study : 1 . Subject must able understand provide inform consent . 2 . Males female , 1835 year age . 3 . New onset T1D longer 120 day time randomization . 4 . Affected T1D , accord ADA standard criterion , confirm positivity least one T1Dassociated autoantibody , GAD65 , IA2 , ZnT8 , insulin autoantibody ( patient treat insulin le 2 week ) . 5 . Being insulin therapy . 6 . Stimulated Cpeptide peak level &gt; 0.2 nmol/L baseline 1 visit MMTT . 7 . Female subject childbearing potential must negative pregnancy test upon study entry . 8 . Female ( male ) subject reproductive potential must agree use two FDA approve method birth control entire duration study . 9 . Adequate venous access support study require blood draw . Potential participant must meet follow exclusion criterion : 1 . Inability unwillingness participant give write informed consent comply study protocol . 2 . BMI &gt; 30 Kg/m2 . 3 . Contraindications ATG , GCSF , exenatide , etanercept IL2 ( per package insert , e.g. , knowledge hypersensitivity drug excipients ) . 4 . Uncompensated heart failure , fluid overload , myocardial infarction liver disease severe impairment vital organ within last 6 week enrollment . 5 . Any following laboratory finding : hemoglobin &lt; 10.0 g/dL ; leukocytes &lt; 3,000/μL ; neutrophil &lt; 1,500/μL ; lymphocyte &lt; 800/μL ; platelet &lt; 100,000/μL . 6 . Any sign diagnosis significant chronic active infection ( e.g. , hepatitis , tuberculosis , EBV , CMV ) , screen laboratory evidence consistent significant chronic active infection ( positive HIV , IGRA test TB , hepatitis BC ) . 7 . Ongoing acute infection , e.g. , acute respiratory tract urinary tract , gastrointestinal tract infection . 8 . Ongoing anticipate use diabetes medication insulin . 9 . Current ongoing use noninsulin pharmaceutical affect glycemic control within prior 7 day screen . 10 . Current prior use immunomodulators systemic steroid last 2 month could potentially affect diabetes immunologic status . 11 . Recent recipient license investigational live attenuate vaccine ( ) within 6 week randomization . 12 . Use investigational drug within 3 month participation . 13 . Concomitant therapy immunosuppressive drug , immunomodulators , cytotoxic agent , previous therapy le 3 month randomization . 14 . History diagnosis malignancy . Any history gastroparesis severe gastrointestinal disease , pancreatitis , thyroid nodule malignancy exception history localize basal cell carcinoma . 15 . Presence allograft . 16 . AST , ALT Alkaline Phosphatase &gt; 2 time upper limit normal total bilirubin &gt; 1.5 time upper limit normal . 17 . Current , diagnose , mental illness current , diagnosed selfreported drug alcohol abuse ; situation , opinion investigator , would interfere participant 's ability comply study requirement . 18 . Pregnancy ongoing breastfeed woman ; unwillingness inability female male childbearing age use reliable effective form contraception , entire duration study . 19 . Past current medical problem , finding physical examination , laboratory testing , list , opinion investigator , may pose additional risk participation study , may interfere participant 's ability comply study requirement may impact quality interpretation data obtain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>